$0.35
1.94% yesterday
Nasdaq, Aug 12, 10:16 pm CET
ISIN
US92941V1008
Symbol
VYNE

VYNE Therapeutics Inc Stock price

$0.35
-0.98 73.87% 1M
-2.16 86.16% 6M
-3.00 89.63% YTD
-1.33 79.32% 1Y
-5.33 93.88% 3Y
-114.13 99.70% 5Y
-2,066.77 99.98% 10Y
-2,066.77 99.98% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.01 1.94%
ISIN
US92941V1008
Symbol
VYNE
Industry

Key metrics

Basic
Market capitalization
$6.3m
Enterprise Value
$-21.9m
Net debt
positive
Cash
$28.2m
Shares outstanding
16.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.3 | 8.8
EV/Sales
negative | negative
EV/FCF
0.6
P/B
0.1
Financial Health
Equity Ratio
77.9%
Return on Equity
-76.5%
ROCE
-103.0%
ROIC
-199.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$610.0k | $714.0k
EBITDA
$-45.4m | $-44.9m
EBIT
$-45.5m | $-41.1m
Net Income
$-42.2m | $-16.7m
Free Cash Flow
$-37.5m
Growth (TTM | estimate)
Revenue
45.2% | 42.8%
EBITDA
- | -2.9%
EBIT
-47.8% | 5.8%
Net Income
-45.1% | 58.1%
Free Cash Flow
-34.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-7,511.4% | -6,285.7%
EBIT
-7,513.1%
Net
-6,974.6% | -2,337.0%
Free Cash Flow
-6,190.3%
More
EPS
$-1.0
FCF per Share
$-2.3
Short interest
2.0%
Employees
13
Rev per Employee
$40.0k
Show more

Is VYNE Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

VYNE Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a VYNE Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a VYNE Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from VYNE Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.61 0.61
45% 45%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
9% 9%
2,080%
- Research and Development Expense 33 33
93% 93%
5,469%
-45 -45
-
-7,449%
- Depreciation and Amortization 0.01 0.01
-
2%
EBIT (Operating Income) EBIT -45 -45
48% 48%
-7,451%
Net Profit -42 -42
45% 45%
-6,918%

In millions USD.

Don't miss a Thing! We will send you all news about VYNE Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VYNE Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib BRIDGEWATER, N.J., July 30, 2025 (G...
Neutral
GlobeNewsWire
about one month ago
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Ad...
Neutral
GlobeNewsWire
3 months ago
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet...
More VYNE Therapeutics Inc News

Company Profile

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

Head office United States
CEO David Domzalski
Employees 13
Founded 2011
Website vynetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today